Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes

NCT05057299 | Completed

• 1 other identifier: 20 KHCC 169
• Study Type: observational
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with extramedullary leukemia were identified over 10 years (January 2003 to September 2019). Clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.

Conditions

Acute Myeloid Leukemia

Keywords

AML; leukemia,; myeloid sarcoma; extramedullary disease

Outcome Measures

Primary Outcomes (1)

• Overall survival (OS),

  To calculate the median and estimated 4-year overall survival

  "4 year, year 4"

Secondary Outcomes (1)

• Progression-Free Survival

  "4 year, year 4"

Study Arms (1)

Patients with extramedullary leukemia(eAML) with myeloid neoplasms

Other: retrospective data analysis

Interventions

retrospective data analysis OTHER

chart review, analysis and reporting outcomes

Patients with extramedullary leukemia(eAML) with myeloid neoplasms

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: males and females
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with eAML and treated at medical oncology department of KHCC-lymphoma section between January 2003-september 2019.Patients identified by searching KHCC registry databases, using key terms of myeloid sarcoma, granulocytic sarcoma, chloroma, AML, MDS, MPN, relapse. All clinicopathological and molecular data were collected and cases, that satisfied the WHO criteria for the diagnosis of myeloid sarcoma were included in the study. The clinicopathological data included age, sex, prior diagnoses and treatment, disease location, phenotype using flow cytometry or immunohistochemistry, status of bone marrow disease (prior, concurrent or after diagnosis of eAMl), treatment for eAML and their overall survival.

You may qualify if:

• Adult subjects aged ≥18 year and up to 75 years
• Male and females.
• Initially diagnosed and treated with extramedullary leukemia at KHCC and followed till last encounter.
• Patients, who underwent an allogeneic stem cell transplant.
• Period January 2003-September 2019

You may not qualify if:

• Pediatric patients \<18 year of age
• Patients, who lost their follow up within study period.

Sponsors & Collaborators

• King Hussein Cancer Center: lead

Study Sites (1)

King Hussein Cancer Center

Amman, 11941, Jordan

Location

Related Publications (2)

• Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019 Jul;36:70-87. doi: 10.1016/j.blre.2019.04.005. Epub 2019 Apr 29.

  PMID: 31101526 BACKGROUND

• Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Rev. 2021 May;47:100773. doi: 10.1016/j.blre.2020.100773. Epub 2020 Oct 30.

  PMID: 33213985 RESULT

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Leukemia; Sarcoma, Myeloid

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Sarcoma; Neoplasms, Connective and Soft Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Consultant, Medical Oncologist-BMT consultant

Study Record Dates

• First Submitted: September 2, 2021
• First Posted: September 27, 2021
• Study Start: October 1, 2020
• Primary Completion: January 1, 2021
• Study Completion: January 1, 2021
• Last Updated: September 27, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

JO (1)